CN109123631A - It is a kind of improve immunity compound health edible composition and its application - Google Patents
It is a kind of improve immunity compound health edible composition and its application Download PDFInfo
- Publication number
- CN109123631A CN109123631A CN201810989271.2A CN201810989271A CN109123631A CN 109123631 A CN109123631 A CN 109123631A CN 201810989271 A CN201810989271 A CN 201810989271A CN 109123631 A CN109123631 A CN 109123631A
- Authority
- CN
- China
- Prior art keywords
- water
- edible composition
- compound health
- glucan
- improving immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 230000036039 immunity Effects 0.000 title claims abstract description 61
- 230000036541 health Effects 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 58
- 229920001503 Glucan Polymers 0.000 claims abstract description 39
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 31
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 31
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 31
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 29
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 29
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 23
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims abstract description 22
- 239000000047 product Substances 0.000 claims abstract description 22
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000012263 liquid product Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 83
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 102000003886 Glycoproteins Human genes 0.000 claims description 12
- 108090000288 Glycoproteins Proteins 0.000 claims description 12
- 150000002772 monosaccharides Chemical class 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 238000012859 sterile filling Methods 0.000 claims description 5
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 229940107666 astragalus root Drugs 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 206010022000 influenza Diseases 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 241001061264 Astragalus Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 235000006533 astragalus Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002651 drug therapy Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000004233 talus Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 230000010148 water-pollination Effects 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 150000002402 hexoses Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920001221 xylan Polymers 0.000 description 3
- 150000004823 xylans Chemical class 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- -1 Acyl neuraminic acid Chemical compound 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical group C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of compound health edible composition for improving immunity and its applications, the edible composition includes albumen powder, fucose, glucan, gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, and above components content is 10-1000mg.Edible composition of the invention can use liquid product and solid-state product preparation method carries out production.Described edible composition and products thereof all has the apparent effect for fundamentally improving immunity.
Description
Technical field
The present invention relates to the edible composition for improving immunity and its applications, in particular to a kind of to improve the compound of immunity
Edible health composition and its application.
Background technique
Modern industry large quantity of exhaust gas discharges the destruction for causing earth atmosphere.Global warming, greenhouse effects, glacier are melted
Change, sea-level rise, various natural calamity aggravations, harmful substance excessive emissions make air, soil, pollution of waterhead.It is each, two
Year primary extensive wreak havoc etc. because of epidemic disease caused by bacterium, virus seriously annoyings the health of the mankind.Modern civilization is to people
Class brings material enjoyment, fundamentally changes the mankind original life style and habit, while also bringing largely to the mankind
Negative effect.Nutrient imbalance and surplus cause various metabolic disorders, and vivotoxin excretion is obstructed, and induce cardiovascular and cerebrovascular disease；
The environment of indoor four seasons temperature control makes acarid, aphid, spore class and various bacteriums, viral mass propagation, swims in air, passes through
Respiratory tract enters in human body.Furniture, interior decoration, the art work of modernization are corroded entrainment of harmful carcinogen such as formaldehyde
The health etc. of the mankind.
Immunity is the defense mechanism of human body itself, is that human bioequivalence and any foreign matter of the external intrusion of elimination are (viral, thin
Bacterium etc.), it handles aging, damage, death, the own cells of denaturation and identification and processing vivo mutations cell and virus infection is thin
The ability of born of the same parents.
Immunology Today thinks that immunity is human bioequivalence and the physiological reaction for excluding " dissident ".This is executed in human body
Function is immune system.Over millions of years, the environment that human lives are not only suitble to existence but also are fraught with risks at one, the mankind are obtained
With survival, outstanding immunity is also obtained.Thus immunity is the product of biological evolution process.
The mankind will have the pest resistance for resisting various viruses, bacterium, create the physique of health, most important is enhancing itself
Natural immunity and natural curability to various diseases.
Most directly showing for hypoimmunity is exactly liable to illness.Because of frequent illness, the consumption of body is aggravated, so one
As have a delicate constitution, the performance such as malnutritive, apathetic, fatigue and weak, loss of appetite, sleep disturbance.It is sick, have an injection and take medicine
Homely food is become.It is sick every time to be lot more time to restore, and usually recurrent exerbation.It if things go on like this will lead to body
Body and intellectual development are bad, also easily induce major disease.
The Chinese patent of Publication No. CN108065414A disclose a kind of edible composition with strengthen immunity and
It is applied.The practical composition includes pea separation protein, Fructus Hippophae polysaccharide, fucoidin.The mass ratio of said combination
For 1:0.35 ~ 0.6:1.1 ~ 1.8.The edible composition and its food all has the good work for significantly increasing immunity
With.
The above-mentioned edible composition referred in the prior art is mentioned to can preferably be mentioned when using the edible composition
High immunity, but the reason of most people hypoimmunity, is as follows: first is that the function of synthesis immunocyte or raw material lack in vivo
It loses, so as to cause the negligible amounts of vivo immunization cell, immune system cannot play its due effect；Second is that vivo immunization is thin
The glycoprotein of cellular surface lacks cannot identify alien material so as to cause immunocyte well, low so as to cause immunocompetence
Under.
When human body itself lacks the substance that immunocyte generates, and the ability of human body itself synthesis immunocyte is stronger
When, it can be good at providing the raw material of production immunocyte to human body by the above-mentioned edible composition referred to, to mention
The immunity of high human body.But immunocyte surface glycoprotein lacks, and when human body cannot synthesize glycoprotein well, above-mentioned food
Only palliative with composition, when not using above-mentioned edible composition, body immunity will gradually glide, Bu Nengcong
Fundamentally improve the immunity of the human body.
Summary of the invention
The object of the present invention is to provide a kind of compound health edible compositions for improving immunity.This raising immunity
Compound health edible composition can be improved the immunity of the human body fundamentally.
It is another object of the present invention to be to provide the compound health edible composition solid-state product of above-mentioned raising immunity
Preparation method.
It is another object of the present invention to be to provide above-mentioned raising immunity to meet edible health composition liquid product
Preparation method.
Preferred embodiment according to the present invention mainly includes following component: egg in the edible composition of the invention
White powder, fucose, glucan, gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Radix Astragali
Extract, above components content are 10-1000mg.Wherein fucose comes from raw material fucoidin extract, the glucan
From raw material beer yeast powder, the monosaccharide includes gucosamine, galactolipin, and wherein gucosamine is mentioned from various fish
It takes, galactolipin comes from material plant glue.The xylose in the plant, while exist in animal heparin, chondroitin and
In glycoprotein.
The effect of every component is as follows:
(1) fucose: being one kind of hexose, also known as 6- deoxidation-L- galactolipin, and can regard a kind of methylpentose as.
The fucose overwhelming majority existing for nature is L- fucose, and the fucose of D configuration is only used as rare sugar, is found in some sugar
In sweet class compound.Fucose few hydroxyl on the 6th carbon atom than general hexose, so fucose is than other monosaccharide
Hydrophily is weak, and hydrophobicity is more by force.Its effect is as follows: nerve conduction, immunological regulation, the growth for inhibiting cancer and transfer are exhaled
Inhale the adjusting of the prevention and treatment, collagen of road infection.
(2) galactolipin (CH2OH(CHOH)4CHO): being a kind of galactolipin of monosaccharide in plant kingdom's often presence in the form of polysaccharide
In various plants glue.Sweetener and excipient in medical industry, for drug;In addition, can also make bacteria culture media.It
Often it is present in the form of D- galactoside in brain and nerve fiber and the important component of certain glycoprotein, in enteron aisle
Absorbing most fast monosaccharide is galactolipin.
(3) mannose: being a kind of monosaccharide and a kind of hexose.It, can be because of hexokinase during carbohydate metabolism
Effect, and phosphorylation forms Man-6-P.Molecular formula is C5H11O5CHO.Mannose cannot good generation in human body
It thanks.So oral rear mannose enters carbohydate metabolism process and is not obvious, it, all can be by body even if the g mannose being externally entering
Intracorporal tissue is realized.Its physiological effect in human body is as follows: 1) adjusting immune system；2) Macrophage Surface has 4 kinds of receiving
Device can capture antigen, there is mannose component；3) increase wound healing；4) anti-inflammatory effect；5) inhibit tumour growth and turn
It moves, increases cancer survival rate；It 6) can be to avoid certain bacterium infections, such as urethral infection.
(4) gucosamine: i.e. Glucosamine, the compound that a hydroxyl of glucose is replaced by an amino.Molecule
Formula C6H13O5N is commonly called as amino sugar.Glucosamine is often used in the diet adjuvant treatment of osteoarthritis, but curative effect is still
There is certain dispute.
(5) xylose: xylose is a component of xylan, and xylan is widely present in plant.Xylose exists in dynamic
In object heparin, chondroitin and glycoprotein, it is the connection unit of sugar chain and serine (or threonine) in certain glycoprotein.Certainly
Right boundary does not find the xylose of free state also so far.
(6) Astragalus Root P.E: for the drying root extract of leguminous plant Radix Astragali.With strengthen immunity, enhance energy, resists
Fatigue, anti-mutation, liver protection inhibit the effect of osteoclast.Astragalus polyose has reducing blood lipid, i.e. reduction cholesterol and glycerol three
The effect of ester, increasing high density lipoprotein;Cardiovascular and cerebrovascular disease can be prevented and treated, such as atherosclerosis, coronary artery
Lesion, peripheral angiopathy and hyperlipidemia etc..Astragaloside IV has significant decrease blood glucose, glycosylated hemoglobin and Urine proteins
Effect, the AGEs in cortex renis and serum can be reduced, display Astragaloside IV has antioxidation, and has to aldose reductase
Inhibiting effect, there are also the effects for inhibiting proliferation of mesangial cells, mitigating renal hypertrophy.Appropriate auxiliary material is added in Astragaloside IV, it can
Oral preparation is made, it is for preventing and treating diabetic nephropathy.
(7) glucan: glucan refers to the homotype polysaccharide formed using glucose as monosaccharide, with glucosides between glucose unit
Key connection.The polysaccharide that beta glucan active structure is made of glucose unit, most of they are combined by β -1,3, this
It is the mode of glucose chain link.It can activated macrophage, neutrophils etc., therefore leukin, thin can be improved
The content of born of the same parents' mitogen and distinct antibodies stimulates the immune system of body comprehensively.So, body, which just has, more is ready to resist
Disease caused by microorganism.The ability that beta glucan can make the lymphocyte of injured body generate cell factor (IL-1) is extensive rapidly
It is multiple normal, effectively adjust human body immune function.Many experiments show that beta glucan can promote the generation of internal IgM antibody, to mention
The immunocompetence of high body fluid.The cell of this glucan activation can excite the non-specific defense mechanism of host, thus apply tumour,
It is deep in terms of infection disease and treatment wound to attract attention.
(8) acetylgalactosamine: the group as the glycoprotein and proteoglycan for constituting zooblast and tissue supports matter
Saccharogenesis.
(9) n acetylneuraminic acid n: invading germ according to playing the role of " inducing ", and cognition at present is that the transmitting of gangliosides is passed
Matter, and be the component part of brain.Sialic acid can prevent germ from invading.Sialic acid is also the receptor of influenza virus simultaneously,
It is the binding site that influenza virus is incorporated in mucilage cell.
Specific embodiment according to the present invention, the edible composition combined effect principle of the invention are as follows:
(1) fucose of the present invention, glucan, galactolipin, Astragalus Root P.E, albumen powder are experiments have shown that can significantly mention
The main component of high body immunity.Wherein, the albumen powder is that the routine proteins such as soybean protein isolate, lactalbumin extract
It is extracted in object.Astragalus Root P.E is astragalus polyose.Fucose has nerve conduction, immunoregulatory basic function, but rock algae
Sugar itself hydrophily is weak, hydrophobicity is strong, when preparing edible composition fucose cannot with water is sufficiently miscible will lead to rock algae
Sugar is unevenly distributed, to cause to be lost during the preparation process, and is unfavorable for absorption of human body.Glucan have activated macrophage,
Neutrophils stimulate the function of the immune system of body.Glucan is that glucosan polymerize the polysaccharide to be formed, and is had good
Hydrophily.Galactolipin is the important composition ingredient of the glycoprotein of human immunocyte surface identification, and is easy to be inhaled by human body
It receives.It will appear suspension when said components are directly miscible in water, so as to cause miscible unevenness.
To solve the above problems, the gucosamine added in component has amino, can be formed with water when dissolving in water
Hydrogen bond, thus sufficiently miscible with water.Meanwhile gucosamine itself is used as organic monosaccharide, can join said components as tie
Knot together, balances hydrophily, the hydrophobic difference of above-mentioned different component, so that the new system distribution formed is uniform.
The edible composition further includes mannose.Mannose can form hydrogen bond with water as monosaccharide, and make simultaneously
For the tie of other components.It is consistent with the effect of gucosamine, while metabolic effects in human body itself is unobvious.
To solve the above problems, the edible composition also added xylose.The free state of xylose is unstable, can send out
Raw polymerization forms xylan, while the connection unit as the sugar chain of immunocyte surface glycoprotein and serine in human body.
The presence of xylose can identify the process of immunocyte synthesis, while xylose can carry mannose as connection unit and enter
At the position of immunocyte synthesis, to preferably absorb mannose, the utilization rate of mannose is improved.
The edible composition further includes acetylgalactosamine, n acetylneuraminic acid n.Acetylgalactosamine is that human body closes
At the important component of glycoprotein.Human body itself is difficult to convert to obtain acetylgalactosamine, and needs through external intake, especially
For its body weak for immunocompetence.
N acetylneuraminic acid n is the receptor of influenza virus, is binding site of the influenza virus in immunocyte.Pass through second
Acyl neuraminic acid can sufficiently identify virus, so that glycoprotein can effectively identify adventitious viruses, stimulate immune system
Adventitious viruses are killed in work.
The preparation method of specific embodiment according to the present invention, the edible composition can have solid-state product system
Preparation Method, liquid product preparation method.
(1) liquid product preparation method includes the following steps:
1) 1000-5000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 100-150 DEG C of high-temperature boiling sterilization；And by after sterilization obtained be water-cooled to 10 DEG C with
Under；
3) ingredient: at normal temperature, by 10-1000mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, Radix Astragali
Extract, glucan, acetylgalactosamine, n acetylneuraminic acid n be added in step 2 it is purified be cooled to 10 DEG C it is below
In water, it is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile filling.
The foreign matters such as impurities in water and bacterium are removed using conventional purifying water process technique in step 1 and step 2.Step 3
It is middle that edible composition component is added into cooling water.It will be water-cooled to that 10 DEG C below the reason is that each component exists in step 3
Its molecular motion is slower under low temperature, is conducive to coming into full contact with for each component.Step 4 is stirred well to water and rises again to room temperature.?
When beginning, molecular motion is slower, and the speed that each component dissolves in water is slow.The molecule of each component dissolution can come into full contact with
It is miscible.Can be established when water temperature slowly improves, between the molecule of each component hydrogen bond etc. connection key mapping so that molecule it
Between there is the sufficient time to be coupled.Water temperature improves, molecular motion aggravation, so that remaining fraction component accelerates dissolution,
Improve preparation efficiency.
(2) the step of solid-state product preparation method is as follows:
1) 1000-5000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 100-150 DEG C of high-temperature boiling sterilization；And by after sterilization obtained be water-cooled to 10 DEG C with
Under；
3) ingredient: at normal temperature, by 10-1000mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, Radix Astragali
Extract, glucan, acetylgalactosamine, n acetylneuraminic acid n be added in step 2 it is purified be cooled to 10 DEG C it is below
In water, it is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5): sterile wind 3-5h is passed through under gnotobasis, room temperature, for accelerating the volatilization of water；
6): to precipitation crystallization in water volatilization process until water volatilizees completely, collecting the crystallization of precipitation；
7): the crystallization gathered is utilized into the extrusion molding of pharmacy extruder, finished product.
It is passed through sterile wind in step 5 and accelerates the evaporation rate of water, to accelerate the precipitation of crystallization.Step 6 and step 7 are medicine
The customary preparation methods of product are applied in the present invention.
In conclusion the invention has the following advantages:
Edible composition of the invention have the function of well fundamentally solve strengthen immunity, be particularly splendid be from
The glycoprotein on immunocyte surface is started with, and from cell recognition direction to immune function of human body is improved, fundamentally solves immune function
The problem of energy difference.In addition, in preparation method using water at low temperature go up the whipping process to room temperature realize each component molecular it
Between come into full contact with reaction so that the distribution of each component is uniform in edible composition, stability is good.
Specific embodiment
In order to illustrate more clearly of the present invention, below with reference to preferred embodiment, the present invention is described further.Ability
Field technique personnel should be appreciated that following specifically described content is illustrative and be not restrictive, this should not be limited with this
The protection scope of invention.
Embodiment 1: the edible composition of immunity is improved
It is a kind of improve immunity compound health edible composition, mainly include following component: albumen powder, fucose, glucan,
Gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, above components content
It is 10-1000mg.
Embodiment 2: the edible composition of immunity is improved
It is a kind of improve immunity compound health edible composition, mainly include following component: albumen powder, fucose, glucan,
Gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, above components content
It is 50-900mg.
Embodiment 3: the edible composition of immunity is improved
It is a kind of improve immunity compound health edible composition, mainly include following component: albumen powder, fucose, glucan,
Gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, above components content
It is 100-800mg.
Embodiment 4: the edible composition of immunity is improved
It is a kind of improve immunity compound health edible composition, mainly include following component: albumen powder, fucose, glucan,
Gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, above components content
It is 150-700mg.
Embodiment 5: the edible composition of immunity is improved
It is a kind of improve immunity compound health edible composition, mainly include following component: albumen powder, fucose, glucan,
Gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, above components content
It is 200-600mg.
Embodiment 6: the edible composition of immunity is improved
It is a kind of improve immunity compound health edible composition, mainly include following component: albumen powder, fucose, glucan,
Gucosamine, galactolipin, mannose, xylose, acetylgalactosamine, n acetylneuraminic acid n, Astragalus Root P.E, above components content
It is 250-500mg.
Comparative example 1:
Using fucose, glucan, galactolipin, Astragalus Root P.E, albumen powder as composition A, each component content is 10-
1000mg, using fucose, mannose, glucan, galactolipin, Astragalus Root P.E, albumen powder as composition B, each component content is
10-1000mg.It is combination with albumen powder, fucose, glucan, gucosamine, galactolipin, mannose, xylose, Astragalus Root P.E
Object C, each component content are 10-1000mg.
Embodiment 7: the effectiveness test of immunity is improved
The method of experiment is divided into experimental group and control group, and experimental group takes the edible combination of the present invention for improving immunity
Object, control group take composition A, composition B, composition C in comparative example.
Experiment group selection is not suffering from 120 people of normal person of influenza, is divided into 6 groups, i.e., first group ~ the 6th group, takes reality respectively
Apply a composition for 1- embodiment 6.Dose is content specified in everyone each each embodiment, once a day.Continuous clothes
With 1 month, and the fixed 8:00 in the morning of Time of Administration section, it is observed 1 month after stopping using.
Control group selection is not suffering from 60 people of normal person of influenza, is divided into 3 groups, i.e., and the 7th group, the 8th group, the 9th group.Wherein
7th group is taken composition A；8th group is taken composition B, and the 9th group is taken composition C.Dose is everyone each 10-
1000mg, once a day.It continuously takes 1 month, and the fixed 8:00 in the morning of Time of Administration section, is observed 1 month after stopping using.
The influenza frequency, symptoms last number of days and drug therapy number of days of experimental group and control group are tested,
Simultaneously to the influenza frequency of one month after stopping using, influenza time interval number of days is tested twice.
1 month period of control group of daily ingestion of composition A, composition B, composition C, influenza frequency reduce 0.1-
0.15 times, 0.2-0.3 times of symptoms last number of days reduction, 0.1-0.15 times of drug therapy number of days reduction, and one after stopping using
Influenza frequency reduces 0.1-0.2 times in a month, and influenza time interval number of days increases 0.2-0.3 times twice.With certain
Fundamentally improve the effect of immunity.
During daily experimental group 1 month, influenza frequency reduces 0.6-0.9 times, and symptoms last number of days reduces 0.8-1.0
Times, drug therapy number of days reduces 0.3-0.5 times, and influenza frequency reduces 0.5-0.7 times in one month after stopping using,
Influenza time interval number of days increases 0.9-1.0 times twice.Has the effect of obvious preferable fundamentally raising immunity.
In conclusion edible composition of the present invention, can be good at improving immunity, while fundamentally solving
The problem of immunity difference.
Embodiment 8: the liquid product preparation method of the edible composition of immunity is improved, its step are as follows:
1) 1000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 100 DEG C of high-temperature boiling sterilizations；And 10 DEG C or less will be water-cooled to after sterilization obtained；
3) ingredient: at normal temperature, by 10mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, astragalus extraction
Object, glucan, acetylgalactosamine, n acetylneuraminic acid n be added to it is purified in step 2 be cooled in 10 DEG C of water below,
It is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile filling.
Embodiment 9: the liquid product preparation method of the edible composition of immunity is improved, its step are as follows:
1) 2000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 110 DEG C of high-temperature boiling sterilizations；And 10 DEG C or less will be water-cooled to after sterilization obtained；
3) ingredient: at normal temperature, by 50mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, astragalus extraction
Object, glucan, acetylgalactosamine, n acetylneuraminic acid n be added to it is purified in step 2 be cooled in 10 DEG C of water below,
It is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile filling.
Embodiment 10: the liquid product preparation method of the edible composition of immunity is improved, its step are as follows:
1) 5000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 150 DEG C of high-temperature boiling sterilizations；And 10 DEG C or less will be water-cooled to after sterilization obtained；
3) ingredient: at normal temperature, 1000mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, Radix Astragali are mentioned
It takes object, glucan, acetylgalactosamine, n acetylneuraminic acid n to be added to and purified in step 2 is cooled to 10 DEG C of water below
In, it is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile filling.
Embodiment 11: the solid-state product preparation method of the edible composition of immunity is improved, its step are as follows:
1) 1000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 100 DEG C of high-temperature boiling sterilizations；And 10 DEG C or less will be water-cooled to after sterilization obtained；
3) ingredient: at normal temperature, by 10mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, astragalus extraction
Object, glucan, acetylgalactosamine, n acetylneuraminic acid n be added to it is purified in step 2 be cooled in 10 DEG C of water below,
It is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile wind 3h is passed through under gnotobasis, room temperature, for accelerating the volatilization of water；
6) in water volatilization process be precipitated crystallization until water volatilize completely, collect the crystallization of precipitation；
7) crystallization gathered is utilized into the extrusion molding of pharmacy extruder, finished product.
Embodiment 12: the solid-state product preparation method of the edible composition of immunity is improved, its step are as follows:
1) 2500mg temperature is no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 125 DEG C of high-temperature boiling sterilizations；And 10 DEG C or less will be water-cooled to after sterilization obtained；
3) ingredient: at normal temperature, by 500mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, astragalus extraction
Object, glucan, acetylgalactosamine, n acetylneuraminic acid n be added to it is purified in step 2 be cooled in 10 DEG C of water below,
It is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile wind 4h is passed through under gnotobasis, room temperature, for accelerating the volatilization of water；
6) in water volatilization process be precipitated crystallization until water volatilize completely, collect the crystallization of precipitation；
7) crystallization gathered is utilized into the extrusion molding of pharmacy extruder, finished product.
Embodiment 13: the solid-state product preparation method of the edible composition of immunity is improved, its step are as follows:
1) 5000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 150 DEG C of high-temperature boiling sterilizations；And 10 DEG C or less will be water-cooled to after sterilization obtained；
3) ingredient: at normal temperature, 1000mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, Radix Astragali are mentioned
It takes object, glucan, acetylgalactosamine, n acetylneuraminic acid n to be added to and purified in step 2 is cooled to 10 DEG C of water below
In, it is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile wind 5h is passed through under gnotobasis, room temperature, for accelerating the volatilization of water；
6) in water volatilization process be precipitated crystallization until water volatilize completely, collect the crystallization of precipitation；
7) crystallization gathered is utilized into the extrusion molding of pharmacy extruder, finished product.
Comparative example 2: the composition A in comparative example 1, composition B, composition C are utilized respectively above-mentioned liquid product and prepared
Method and solid-state product preparation method are produced.
The effect assessment test result of each embodiment and the raising immunity of comparative example liquid product and solid-state product:
The product that embodiment 8- embodiment 13 and comparative example 2 are produced is as test sample.
Embodiment 8- embodiment 13 selects 120 people of subject of immunocompetence difference, is divided into 6 groups, i.e., the first group ~ the 6th
Group.Dose is content specified in everyone each each embodiment, once a day.It continuously takes 1 month, and Time of Administration section
Fixed 8:00 in the morning, is observed 1 month after stopping using.
Comparative example 2 selects 120 people of subject of immunocompetence difference, is divided into 6 groups, i.e., and the 7th group ~ the 12nd group.Dose
For everyone each 10-1000mg, once a day.It continuously takes 1 month, and the fixed 8:00 in the morning of Time of Administration section, stops making
With rear observation 1 month.
Table 1: immunity effect assessment table is improved
| Tested number | Influenza occurs secondary Number is reduced | Symptoms last number of days It reduces | Drug therapy number of days It reduces | Stream after stopping using Feel frequency to reduce | After stopping using when Between interval number of days increase | |
| Embodiment 8 | 20 | 15 | 16 | 13 | 16 | 17 |
| Embodiment 9 | 20 | 17 | 18 | 15 | 18 | 18 |
| Embodiment 10 | 20 | 19 | 20 | 17 | 20 | 20 |
| Embodiment 11 | 20 | 14 | 15 | 14 | 17 | 18 |
| Embodiment 12 | 20 | 17 | 16 | 17 | 19 | 19 |
| Embodiment 13 | 20 | 19 | 18 | 19 | 20 | 20 |
| Comparative example 2 | 20 | 10 | 11 | 9 | 12 | 14 |
As shown in Table 1, after subject takes the product of embodiment 8- embodiment 13 of the present invention, in tested period, there is 85%
The influenza frequency of subject significantly reduces；There is the symptoms last number of days of 87.5% subject to reduce, there is 80% subject's
Drug therapy number of days is reduced；Influenza frequency after having 90% subject to stop using is reduced；There is 90% subject to stop using
Sick time interval afterwards increases.And the product of comparative example 2 is taken, the influenza frequency of only 50% subject is reduced；Have
The symptoms last number of days of 55% subject is reduced, and has the drug therapy number of days of 45% subject to reduce；There is 60% subject to stop making
Influenza frequency after is reduced；Sick time interval after having 70% subject to stop using increases.Therefore, in conclusion
Edible composition of the present invention has the function of apparent fundamentally raising immunity.
The above embodiment of the present invention be only to clearly illustrate example of the present invention, and not be to the present invention
The restriction of embodiment can also make on the basis of the above description for those of ordinary skill in the art
Other various forms of variations or variation here can not be exhaustive all embodiments, all to belong to skill of the invention
The obvious changes or variations that art scheme is extended out are still in the scope of protection of the present invention.
Claims (10)
1. a kind of compound health edible composition for improving immunity, it is characterized in that: being mentioned including polysaccharide, monosaccharide, albumen powder, Radix Astragali
Take object.
2. a kind of compound health edible composition for improving immunity according to claim 1, it is characterized in that: the polysaccharide
Including fucose, glucan, wherein fucose comes from raw material fucoidin extract, and the glucan comes from raw material brewer's yeast
Powder, the monosaccharide include gucosamine, galactolipin, and wherein gucosamine is extracted from various fish, and galactolipin comes from raw material
Natural plant gum.
3. a kind of compound health edible composition for improving immunity according to claim 1, it is characterized in that: the monosaccharide
It further include mannose.
4. a kind of compound health edible composition for improving immunity according to claim 3, it is characterized in that: the monosaccharide
It further include xylose, the xylose exists in animal heparin, chondroitin and glycoprotein in plant.
5. a kind of compound health edible composition for improving immunity according to claim 1, it is characterized in that: the food
It further include acetylgalactosamine with composition.
6. a kind of compound health edible composition for improving immunity according to claim 1, it is characterized in that: the food
It further include n acetylneuraminic acid n with composition.
7. a kind of compound health edible composition for improving immunity of any one described in -6 according to claim 1, special
Sign is: the constituent content in above-mentioned edible composition is 10-1000mg.
8. it is a kind of improve immunity compound health edible composition application, it is characterized in that: include liquid product preparation method,
Solid-state product preparation method.
9. the application of a kind of compound health edible composition for improving immunity according to claim 8, it is characterized in that: institute
The preparation step for the liquid product preparation method stated is as follows:
1) 1000-5000mg, temperature are no more than to 10 DEG C of water, impurities in water is removed by water purification process；
2) purified water is passed through into 100-150 DEG C of high-temperature boiling sterilization；And by after sterilization obtained be water-cooled to 10 DEG C with
Under；
3) ingredient: at normal temperature, by 10-1000mg fucose, glucan, galactolipin, gucosamine, mannose, xylose, Radix Astragali
Extract, glucan, acetylgalactosamine, n acetylneuraminic acid n be added in step 2 it is purified be cooled to 10 DEG C it is below
In water, it is sufficiently stirred；
4) stop stirring after stirring is risen again to water to room temperature；
5) sterile filling.
10. a kind of application of compound health edible composition for improving immunity according to claim 8, it is characterized in that:
The preparation step of the solid-state product preparation method is as follows:
Step of the step 1- step 4 as shown in claim 9；
5) sterile wind 3-5h is passed through under gnotobasis, room temperature, for accelerating the volatilization of water；
6) in water volatilization process be precipitated crystallization until water volatilize completely, collect the crystallization of precipitation；
7) crystallization gathered is utilized into the extrusion molding of pharmacy extruder, finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810989271.2A CN109123631A (en) | 2018-08-28 | 2018-08-28 | It is a kind of improve immunity compound health edible composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810989271.2A CN109123631A (en) | 2018-08-28 | 2018-08-28 | It is a kind of improve immunity compound health edible composition and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109123631A true CN109123631A (en) | 2019-01-04 |
Family
ID=64828697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810989271.2A Pending CN109123631A (en) | 2018-08-28 | 2018-08-28 | It is a kind of improve immunity compound health edible composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109123631A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103284156A (en) * | 2013-06-20 | 2013-09-11 | 上海西宝生物科技有限公司 | Healthcare product composition and application thereof |
| CN104305214A (en) * | 2014-10-13 | 2015-01-28 | 山东省海洋生物研究院 | Food capable of improving immunity and preparation method thereof |
-
2018
- 2018-08-28 CN CN201810989271.2A patent/CN109123631A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103284156A (en) * | 2013-06-20 | 2013-09-11 | 上海西宝生物科技有限公司 | Healthcare product composition and application thereof |
| CN104305214A (en) * | 2014-10-13 | 2015-01-28 | 山东省海洋生物研究院 | Food capable of improving immunity and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 塞萨尔丁·阿拉萨尔瓦: "《干果的植物化学成分及其保健作用》", 28 February 2018, 中国质检出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111990461A (en) | Mixed milk powder for enhancing immunity and preparation method thereof | |
| CN106822890A (en) | A kind of pharmaceutical composition for preventing and treating diarrhea of weaned piglets and its preparation method and application | |
| CN104083427B (en) | Prevent and treat the compound Radix Astragali polysaccharide particle of bird flu | |
| CN105287790A (en) | Paederia scandens extract and applications thereof | |
| CN103083510A (en) | Chinese medicinal oral liquid for improving poultry immune function and its preparation method | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| JP5897796B2 (en) | Hypoglycemic agent and food and drink for preventing diabetes or improving symptoms comprising the same | |
| CN103860616A (en) | Manyprickle Acathopanax Root extrat, and preparation method and application thereof | |
| CN109123631A (en) | It is a kind of improve immunity compound health edible composition and its application | |
| KR20080009695A (en) | Healthfood and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| CN1879788A (en) | Virus-clearing capsule | |
| CN101212963A (en) | The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells | |
| CN108853026A (en) | A kind of andrographolide for animals is scattered | |
| CN110404021B (en) | Rhizoma polygonati preparation and preparation method thereof | |
| CN105726742A (en) | Anti-neweastle disease virus and anti-avian influenza veterinary herbal medicine and preparation method thereof | |
| CN101703772A (en) | Compound indigowoad root oral liquid for improving poultry immunity and preparation method thereof | |
| CN113648393A (en) | Fermented traditional Chinese medicine composition for preventing salpingitis of laying hens and improving laying performance of laying hens | |
| CN101085048B (en) | Traditional Chinese medicine for detoxicating for animals and preparation method thereof | |
| CN1449753A (en) | Chlorogenic acid and isochlorogenic acid composition and medical use thereof | |
| CN106344645B (en) | Traditional Chinese medicine for livestock immunopotentiator and preparation method | |
| CN116531471B (en) | Traditional Chinese medicine mixture for treating syndrome of damp-heat attacking lung caused by virus infection | |
| CN111135223B (en) | Application of flavored herba Moslae oral liquid in preparation of medicine for treating infantile rotavirus enteritis complicated with myocardial injury | |
| CN115607596B (en) | Health wine with uric acid reducing effect and preparation method thereof | |
| CN101095707A (en) | Use of bupleurum root total polyoses in the preparing of medicine for preventing and treating acute respiratory distress syndrome | |
| RU2473358C1 (en) | Composition possessing adaptogenic, hepatoprotective and immunomodulatory action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190104 |
|
| WD01 | Invention patent application deemed withdrawn after publication |